Lorelei D. Shoemaker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lorelei D. Shoemaker has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Steven D. Chang
Department of Neurosurgery, Stanford University School of Medicine, Stanford, USA
4 shared publications - Gary Kenneth Steinberg
Department of Neurosurgery, Stanford University School of Medicine, Stanford, California, USA
3 shared publications - Breanna M. Allen
Graduate Program in Biomedical Sciences, University of California, San Francisco, San Francisco, USA
2 shared publications Daniel H. Geschwind
Neuropsychiatric Institute - Semel Institute for Neuroscience & Human Behavior and Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America
2 shared publicationsDouglas J. Cook
Centre for Neuroscience Studies and the Department of Surgery, Queen's University, Kingston, Ontario, K7L 3N6
2 shared publicationsGary K. Steinberg
Department of Neurosurgery, Stanford Neuromolecular Innovation Program, Stanford University 300 Pasteur Drive, Stanford, California, 94305
2 shared publications
Latest Publications
- Open Access
- 25 October 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (11) , 1145
Characterizing the Microenvironment of Cerebral Arteriovenous Malformations to Test Novel Treatment Modalities
Brain arteriovenous malformations (bAVMs) consist of a tangled nidus of abnormal dilated vessels characterized by direct connections between arteries and veins that lack an intervening capillary bed, creating a high-to-low flow pressure system that is predisposed to spontaneous hemorrhage with significant associated neurologic morbidity and mortality. Treatment options for bAVMs include the following: surgical resection, intravascular embolization to obliterate blood flow through the AVM, and radiosurgery. Understanding the molecular mechanisms of bAVM formation and factors that predispose it to hemorrhage can lead to novel treatments that can improve the prognosis for patients. This review summarizes emerging insights into the complex and dynamic molecular mechanisms of bAVMs. Dysregulation in key VEGF, TGF-β/BMP9/10–ENG–ALK1–SMAD4, Notch, and MAPK/ERK signaling pathways drive abnormal angiogenesis in both syndromic and sporadic forms, with KRAS/BRAF/MAPK21 mutations specifically linked to the latter. Advances in bAVM-induced animal models have corroborated many of the genetic profiles found in humans, and they continue to provide novel insights into bAVM mechanisms. Collectively, these mechanistic findings are guiding translational advances, with targeted therapies and liquid biopsy approaches emerging as avenues for precision treatment and improved patient outcomes.
- 25 October 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (11) , 1145
Open AccessCharacterizing the Microenvironment of Cerebral Arteriovenous Malformations to Test Novel Treatment Modalities
Brain arteriovenous malformations (bAVMs) consist of a tangled nidus of abnormal dilated vessels characterized by direct connections between arteries and veins that lack an intervening capillary bed, creating a high-to-low flow pressure system that is predisposed to spontaneous hemorrhage with significant associated neurologic morbidity and mortality. Treatment options for bAVMs include the following: surgical resection, intravascular embolization to obliterate blood flow through the AVM, and radiosurgery. Understanding the molecular mechanisms of bAVM formation and factors that predispose it to hemorrhage can lead to novel treatments that can improve the prognosis for patients. This review summarizes emerging insights into the complex and dynamic molecular mechanisms of bAVMs. Dysregulation in key VEGF, TGF-β/BMP9/10–ENG–ALK1–SMAD4, Notch, and MAPK/ERK signaling pathways drive abnormal angiogenesis in both syndromic and sporadic forms, with KRAS/BRAF/MAPK21 mutations specifically linked to the latter. Advances in bAVM-induced animal models have corroborated many of the genetic profiles found in humans, and they continue to provide novel insights into bAVM mechanisms. Collectively, these mechanistic findings are guiding translational advances, with targeted therapies and liquid biopsy approaches emerging as avenues for precision treatment and improved patient outcomes.
- Open Access
- 7 June 2023
- Published by Frontiers Media SA in Frontiers in Human Neuroscience
- Vol. 17, 1212184
Editorial: Brain arteriovenous malformations: cerebrovasculature behaving badly
Editorial: Brain arteriovenous malformations: cerebrovasculature behaving badly
- 7 June 2023
- Published by Frontiers Media SA in Frontiers in Human Neuroscience
- Vol. 17, 1212184
Open AccessEditorial: Brain arteriovenous malformations: cerebrovasculature behaving badly
Editorial: Brain arteriovenous malformations: cerebrovasculature behaving badly
- Open Access
- 21 June 2020
- Published by Wiley in Clinical and Translational Medicine
- Vol. 10 (2)
Evidence for endothelial‐to‐mesenchymal transition in human brain arteriovenous malformations
Background: Brain arteriovenous malformations (AVMs) are rare, potentially devastating cerebrovascular lesions that can occur in both children and adults. AVMs are largely sporadic and the basic disease biology remains unclear, limiting advances in both detection and treatment. This study aimed to investigate human brain AVMs for endothelial‐to‐mesenchymal transition (EndMT), a process recently implicated in cerebral cavernous malformations (CCMs).Methods: We used 29 paraffin‐embedded and 13 fresh/frozen human brain AVM samples to profile expression of panels of EndMT‐associated proteins and RNAs. CCMs, a cerebrovascular disease also characterized by abnormal vasculature, were used as a primary comparison, given that EndMT specifically contributes to CCM disease biology. AVM‐derived cell lines were isolated from three fresh, surgical AVM samples and characterized by protein expression.Results: We observed high collagen deposition, high PAI‐1 expression, and expression of EndMT‐associated transcription factors such as KLF4, SNAI1, and SNAI2 and mesenchymal‐associated markers such as VIM, ACTA2, and S100A4. SMAD‐dependent TGF‐β signaling was not strongly activated in AVMs and this pathway may be only partially involved in mediating EndMT. Using serum‐free culture conditions, we isolated myofibroblast‐like cell populations from AVMs that expressed a unique range of proteins associated with mature cell types and with EndMT. Conditioned medium from these cells led to increased proliferation of HUVECs and SMCs.Conclusions: Collectively, our results suggest a role for EndMT in AVM disease. This may lead to new avenues for disease models to further our understanding of disease mechanisms, and to the development of improved diagnostics and therapeutics.
- 21 June 2020
- Published by Wiley in Clinical and Translational Medicine
- Vol. 10 (2)
Open AccessEvidence for endothelial‐to‐mesenchymal transition in human brain arteriovenous malformations
Background: Brain arteriovenous malformations (AVMs) are rare, potentially devastating cerebrovascular lesions that can occur in both children and adults. AVMs are largely sporadic and the basic disease biology remains unclear, limiting advances in both detection and treatment. This study aimed to investigate human brain AVMs for endothelial‐to‐mesenchymal transition (EndMT), a process recently implicated in cerebral cavernous malformations (CCMs).Methods: We used 29 paraffin‐embedded and 13 fresh/frozen human brain AVM samples to profile expression of panels of EndMT‐associated proteins and RNAs. CCMs, a cerebrovascular disease also characterized by abnormal vasculature, were used as a primary comparison, given that EndMT specifically contributes to CCM disease biology. AVM‐derived cell lines were isolated from three fresh, surgical AVM samples and characterized by protein expression.Results: We observed high collagen deposition, high PAI‐1 expression, and expression of EndMT‐associated transcription factors such as KLF4, SNAI1, and SNAI2 and mesenchymal‐associated markers such as VIM, ACTA2, and S100A4. SMAD‐dependent TGF‐β signaling was not strongly activated in AVMs and this pathway may be only partially involved in mediating EndMT. Using serum‐free culture conditions, we isolated myofibroblast‐like cell populations from AVMs that expressed a unique range of proteins associated with mature cell types and with EndMT. Conditioned medium from these cells led to increased proliferation of HUVECs and SMCs.Conclusions: Collectively, our results suggest a role for EndMT in AVM disease. This may lead to new avenues for disease models to further our understanding of disease mechanisms, and to the development of improved diagnostics and therapeutics.
- 22 January 2018
- Published by Wolters Kluwer Health in Stroke
- Vol. 49 (Suppl_1)
Abstract 74: Analysis of Genome-Wide Blood DNA Methylation Profile in Moyamoya Disease
Background: Moyamoya disease (MMD) is a rare cerebrovascular disorder of unknown cause. Epigenetic regulations such as methylation play key role in gene expression and cerebrovascular diseases, however, methylation changes in MMD has not been previously reported. To understand the methylation profile of MMD, we performed a genome-wide DNA methylation analysis of whole blood from MMD patients. Method: Twenty-eight female adult patients and age-/sex- matched 10 healthy control volunteers (34.2 ± 1.3y) were included. All patients developed TIA or headache and were diagnosed as typical MMD (n=19 and 9), predominantly with Suzuki’s angiographical stage 3. DNA was extracted from frozen whole blood and processed with bisulfide conversion. Genome-wide DNA methylation profile was screened using Illumina 850K EPIC microarray. Blood DNA methylome and clinical characteristics were analyzed. Results: Self-declared race was predominantly Asian or Caucasian (n=14 and 13 in MMD, n=6 and 3 in control). Eleven patients showed asymptomatic cerebral infarct. MMD susceptible variant (rs112735431) was confirmed only in 4 Asian MMD. We observed distinct blood DNA methylation profile between Asian and Caucasian. There was no significant correlation between the methylation profile and symptom, infarct lesion, nor MMD susceptible variant. Our data revealed 51% of differentially methylated CpG probes (DMPs) in Caucasian MMD (PConclusion: Our results indicate that significant methylation changes occur in the blood of MMD patients. In Caucasian MMD, circulating T lymphocytes and monocytes may have a role in disease development, since these cells are known to participate in thickened fibrocellular intima in MMD. Ongoing studies are identifying the correlation of DNA methylation in blood and gene expression in the vascular tissue. Blood DNA methylation changes may be related with the risk of Caucasian MMD.
- 22 January 2018
- Published by Wolters Kluwer Health in Stroke
- Vol. 49 (Suppl_1)
Abstract 74: Analysis of Genome-Wide Blood DNA Methylation Profile in Moyamoya Disease
Background: Moyamoya disease (MMD) is a rare cerebrovascular disorder of unknown cause. Epigenetic regulations such as methylation play key role in gene expression and cerebrovascular diseases, however, methylation changes in MMD has not been previously reported. To understand the methylation profile of MMD, we performed a genome-wide DNA methylation analysis of whole blood from MMD patients. Method: Twenty-eight female adult patients and age-/sex- matched 10 healthy control volunteers (34.2 ± 1.3y) were included. All patients developed TIA or headache and were diagnosed as typical MMD (n=19 and 9), predominantly with Suzuki’s angiographical stage 3. DNA was extracted from frozen whole blood and processed with bisulfide conversion. Genome-wide DNA methylation profile was screened using Illumina 850K EPIC microarray. Blood DNA methylome and clinical characteristics were analyzed. Results: Self-declared race was predominantly Asian or Caucasian (n=14 and 13 in MMD, n=6 and 3 in control). Eleven patients showed asymptomatic cerebral infarct. MMD susceptible variant (rs112735431) was confirmed only in 4 Asian MMD. We observed distinct blood DNA methylation profile between Asian and Caucasian. There was no significant correlation between the methylation profile and symptom, infarct lesion, nor MMD susceptible variant. Our data revealed 51% of differentially methylated CpG probes (DMPs) in Caucasian MMD (PConclusion: Our results indicate that significant methylation changes occur in the blood of MMD patients. In Caucasian MMD, circulating T lymphocytes and monocytes may have a role in disease development, since these cells are known to participate in thickened fibrocellular intima in MMD. Ongoing studies are identifying the correlation of DNA methylation in blood and gene expression in the vascular tissue. Blood DNA methylation changes may be related with the risk of Caucasian MMD.
- Open Access
- 1 February 2016
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 15 (2) , 344-354
Neural Stem Cells (NSCs) and Proteomics
- 1 February 2016
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 15 (2) , 344-354
Open AccessNeural Stem Cells (NSCs) and Proteomics
- Open Access
- 1 January 2016
- Published by Oxford University Press (OUP) in G3: Genes, Genomes, Genetics
- Vol. 6 (1) , 41-49
Disease Variant Landscape of a Large Multiethnic Population of Moyamoya Patients by Exome Sequencing
Moyamoya disease (MMD) is a rare disorder characterized by cerebrovascular occlusion and development of hemorrhage-prone collateral vessels. Approximately 10–12% of cases are familial, with a presumed low penetrance autosomal dominant pattern of inheritance. Diagnosis commonly occurs only after clinical presentation. The recent identification of the RNF213 founder mutation (p.R4810K) in the Asian population has made a significant contribution, but the etiology of this disease remains unclear. To further develop the variant landscape of MMD, we performed high-depth whole exome sequencing of 125 unrelated, predominantly nonfamilial, ethnically diverse MMD patients in parallel with 125 internally sequenced, matched controls using the same exome and analysis platform. Three subpopulations were established: Asian, Caucasian, and non-RNF213 founder mutation cases. We provided additional support for the previously observed RNF213 founder mutation (p.R4810K) in Asian cases (P = 6.01×10−5) that was enriched among East Asians compared to Southeast Asian and Pacific Islander cases (P = 9.52×10−4) and was absent in all Caucasian cases. The most enriched variant in Caucasian (P = 7.93×10−4) and non-RNF213 founder mutation (P = 1.51×10−3) cases was ZXDC (p.P562L), a gene involved in MHC Class II activation. Collapsing variant methodology ranked OBSCN, a gene involved in myofibrillogenesis, as most enriched in Caucasian (P = 1.07×10−4) and non-RNF213 founder mutation cases (P = 5.31×10−5). These findings further support the East Asian origins of the RNF213 (p.R4810K) variant and more fully describe the genetic landscape of multiethnic MMD, revealing novel, alternative candidate variants and genes that may be important in MMD etiology and diagnosis.
- 1 January 2016
- Published by Oxford University Press (OUP) in G3: Genes, Genomes, Genetics
- Vol. 6 (1) , 41-49
Open AccessDisease Variant Landscape of a Large Multiethnic Population of Moyamoya Patients by Exome Sequencing
Moyamoya disease (MMD) is a rare disorder characterized by cerebrovascular occlusion and development of hemorrhage-prone collateral vessels. Approximately 10–12% of cases are familial, with a presumed low penetrance autosomal dominant pattern of inheritance. Diagnosis commonly occurs only after clinical presentation. The recent identification of the RNF213 founder mutation (p.R4810K) in the Asian population has made a significant contribution, but the etiology of this disease remains unclear. To further develop the variant landscape of MMD, we performed high-depth whole exome sequencing of 125 unrelated, predominantly nonfamilial, ethnically diverse MMD patients in parallel with 125 internally sequenced, matched controls using the same exome and analysis platform. Three subpopulations were established: Asian, Caucasian, and non-RNF213 founder mutation cases. We provided additional support for the previously observed RNF213 founder mutation (p.R4810K) in Asian cases (P = 6.01×10−5) that was enriched among East Asians compared to Southeast Asian and Pacific Islander cases (P = 9.52×10−4) and was absent in all Caucasian cases. The most enriched variant in Caucasian (P = 7.93×10−4) and non-RNF213 founder mutation (P = 1.51×10−3) cases was ZXDC (p.P562L), a gene involved in MHC Class II activation. Collapsing variant methodology ranked OBSCN, a gene involved in myofibrillogenesis, as most enriched in Caucasian (P = 1.07×10−4) and non-RNF213 founder mutation cases (P = 5.31×10−5). These findings further support the East Asian origins of the RNF213 (p.R4810K) variant and more fully describe the genetic landscape of multiethnic MMD, revealing novel, alternative candidate variants and genes that may be important in MMD etiology and diagnosis.
- Open Access
- 18 November 2014
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 1 (12) , 982-995
Human brain arteriovenous malformations express lymphatic‐associated genes
- 18 November 2014
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 1 (12) , 982-995
Open AccessHuman brain arteriovenous malformations express lymphatic‐associated genes
- Open Access
- 21 March 2013
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 8 (1) , 45
Immune response profiling identifies autoantibodies specific to Moyamoya patients
Background: Moyamoya Disease is a rare, devastating cerebrovascular disorder characterized by stenosis/occlusion of supraclinoid internal carotid arteries and development of fragile collateral vessels. Moyamoya Disease is typically diagnosed by angiography after clinical presentation of cerebral hemorrhage or ischemia. Despite unclear etiology, previous reports suggest there may be an immunological component.Methods: To explore the role of autoimmunity in moyamoya disease, we used high-density protein arrays to profile IgG autoantibodies from the sera of angiographically-diagnosed Moyamoya Disease patients and compared these to healthy controls. Protein array data analysis followed by bioinformatics analysis yielded a number of auto-antibodies which were further validated by ELISA for an independent group of MMD patients (n = 59) and control patients with other cerebrovascular diseases including carotid occlusion, carotid stenosis and arteriovenous malformation.Results: We identified 165 significantly (p < 0.05) elevated autoantibodies in Moyamoya Disease, including those against CAMK2A, CD79A and EFNA3. Pathway analysis associated these autoantibodies with post-translational modification, neurological disease, inflammatory response, and DNA damage repair and maintenance. Using the novel functional interpolating single-nucleotide polymorphisms bioinformatics approach, we identified 6 Moyamoya Disease-associated autoantibodies against APP, GPS1, STRA13, CTNNB1, ROR1 and EDIL3. The expression of these 6 autoantibodies was validated by custom-designed reverse ELISAs for an independent group of Moyamoya Disease patients compared to patients with other cerebrovascular diseases.Conclusions: We report the first high-throughput analysis of autoantibodies in Moyamoya Disease, the results of which may provide valuable insight into the immune-related pathology of Moyamoya Disease and may potentially advance diagnostic clinical tools.
- 21 March 2013
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 8 (1) , 45
Open AccessImmune response profiling identifies autoantibodies specific to Moyamoya patients
Background: Moyamoya Disease is a rare, devastating cerebrovascular disorder characterized by stenosis/occlusion of supraclinoid internal carotid arteries and development of fragile collateral vessels. Moyamoya Disease is typically diagnosed by angiography after clinical presentation of cerebral hemorrhage or ischemia. Despite unclear etiology, previous reports suggest there may be an immunological component.Methods: To explore the role of autoimmunity in moyamoya disease, we used high-density protein arrays to profile IgG autoantibodies from the sera of angiographically-diagnosed Moyamoya Disease patients and compared these to healthy controls. Protein array data analysis followed by bioinformatics analysis yielded a number of auto-antibodies which were further validated by ELISA for an independent group of MMD patients (n = 59) and control patients with other cerebrovascular diseases including carotid occlusion, carotid stenosis and arteriovenous malformation.Results: We identified 165 significantly (p < 0.05) elevated autoantibodies in Moyamoya Disease, including those against CAMK2A, CD79A and EFNA3. Pathway analysis associated these autoantibodies with post-translational modification, neurological disease, inflammatory response, and DNA damage repair and maintenance. Using the novel functional interpolating single-nucleotide polymorphisms bioinformatics approach, we identified 6 Moyamoya Disease-associated autoantibodies against APP, GPS1, STRA13, CTNNB1, ROR1 and EDIL3. The expression of these 6 autoantibodies was validated by custom-designed reverse ELISAs for an independent group of Moyamoya Disease patients compared to patients with other cerebrovascular diseases.Conclusions: We report the first high-throughput analysis of autoantibodies in Moyamoya Disease, the results of which may provide valuable insight into the immune-related pathology of Moyamoya Disease and may potentially advance diagnostic clinical tools.
- 1 March 2012
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 70 (3) , 518-525
Clinical Neuroproteomics and Biomarkers
Clinical neuroproteomics aims to advance our understanding of disease and injury affecting the central and peripheral nervous systems through the stud
- 1 March 2012
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 70 (3) , 518-525
Clinical Neuroproteomics and Biomarkers
Clinical neuroproteomics aims to advance our understanding of disease and injury affecting the central and peripheral nervous systems through the stud
- Open Access
- 1 January 2012
- Published by Springer Nature in Medical Gas Research
- Vol. 2 (1) , 11
Potential application of hydrogen in traumatic and surgical brain injury, stroke and neonatal hypoxia-ischemia
This article summarized findings of current preclinical studies that implemented hydrogen administration, either in the gas or liquid form, as treatment application for neurological disorders including traumatic brain injury (TBI), surgically induced brain injury (SBI), stroke, and neonatal hypoxic-ischemic brain insult (HI). Most reviewed studies demonstrated neuroprotective effects of hydrogen administration. Even though anti-oxidative potentials have been reported in several studies, further neuroprotective mechanisms of hydrogen therapy remain to be elucidated. Hydrogen may serve as an adjunct treatment for neurological disorders.
- 1 January 2012
- Published by Springer Nature in Medical Gas Research
- Vol. 2 (1) , 11
Open AccessPotential application of hydrogen in traumatic and surgical brain injury, stroke and neonatal hypoxia-ischemia
This article summarized findings of current preclinical studies that implemented hydrogen administration, either in the gas or liquid form, as treatment application for neurological disorders including traumatic brain injury (TBI), surgically induced brain injury (SBI), stroke, and neonatal hypoxic-ischemic brain insult (HI). Most reviewed studies demonstrated neuroprotective effects of hydrogen administration. Even though anti-oxidative potentials have been reported in several studies, further neuroprotective mechanisms of hydrogen therapy remain to be elucidated. Hydrogen may serve as an adjunct treatment for neurological disorders.